MICONAZOLE 3 COMBINATION PACK
Clinical safety rating: safe
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and fungal cell death.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways involving cytochrome P450 enzymes, particularly CYP3A4. It is excreted mainly as inactive metabolites in bile and feces, with less than 1% excreted unchanged in urine. |
| Excretion | Renal: approximately 10-20% as unchanged drug; fecal: >50% as metabolites; biliary: minor route. The majority is eliminated via feces as metabolites, reflecting hepatic metabolism and biliary excretion. |
| Half-life | Terminal elimination half-life is 20-25 hours (intravaginal administration). This long half-life supports a 3-day dosing regimen, maintaining therapeutic concentrations. |
| Protein binding | Approximately 88-93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 1.4 L/kg, indicating extensive tissue distribution including vaginal mucosa. This supports local and systemic penetration after topical application. |
| Bioavailability | Intravaginal: minimal systemic absorption (~1-2% of dose); oral: ~25-30% but not used systemically due to poor bioavailability and rapid metabolism. |
| Onset of Action | Intravaginal: relief of symptoms (itching, discharge) begins within 24-72 hours. Clinical improvement noted after first dose, but full effect typically by day 3. |
| Duration of Action | Duration of antifungal effect is approximately 72 hours after last dose, with continued suppression of Candida species. Cure usually achieved with 3-day regimen; residual benefits may last 1-3 days post-treatment. |
| Molecular Weight | 416.13 |
Intravaginal: 1 applicatorful (100 mg) at bedtime for 3 consecutive nights.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children ≥12 years: Same as adult dosing. Children <12 years: Safety and efficacy not established. |
| Geriatric use | Same as adult dosing; no specific adjustment needed. |
| 1st trimester | Topical miconazole is generally considered safe in the first trimester with minimal systemic absorption; avoid intravaginal use unless clearly needed. |
| 2nd trimester | Topical and intravaginal use is considered safe in the second trimester; no known fetal risk. |
| 3rd trimester | Topical and intravaginal use is considered safe in the third trimester; avoid high doses near term due to theoretical risk of premature labor with systemic absorption. |
Clinical note
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
| FDA category | Human |
| Placental transfer | Minimal systemic absorption (less than 1.4% of applied dose) with topical use; placental transfer is negligible at therapeutic doses. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Common Effects | vaginal yeast infections |
| Serious Effects |
Hypersensitivity to miconazole or any component of the formulation
| Precautions | Hepatic impairment may require dose adjustment. Caution in patients with known hypersensitivity to azole antifungals. Risk of allergic reactions including anaphylaxis. Potential for skin irritation at application site. Not for ophthalmic or oral use (except as directed). Avoid concurrent use with other azole antifungals that may increase systemic absorption. |
| Food/Dietary | None known. No dietary restrictions required. |
Loading safety data…
| Miconazole exhibits minimal systemic absorption after topical application; concentrations in breast milk are likely negligible. Topical use is considered safe during breastfeeding; avoid application to breast area to prevent infant ingestion. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Pregnancy Category C. Limited human data; no evidence of teratogenicity in animal studies at systemic exposures similar to human doses. Vaginal absorption is minimal; first trimester use generally avoided unless benefit outweighs risk. |
| Fetal Monitoring | No specific monitoring required. Routine prenatal care suffices. For prolonged therapy, assess liver function tests periodically. |
| Fertility Effects | No known effects on fertility. Animal studies show no impairment at systemic levels. |
| Clinical Pearls | The combination pack includes miconazole nitrate cream 2% and miconazole nitrate suppository 200 mg. Ensure patient inserts the suppository at bedtime for 3 consecutive nights and applies cream externally twice daily for 7 days. Advise use of a panty liner. Miconazole may interact with warfarin; monitor INR. Avoid concurrent use of latex condoms or diaphragms as the cream base can weaken latex. Consider checking for pregnancy or other causes of vaginitis if symptoms persist. |
| Patient Advice | Use the suppository at bedtime for 3 nights in a row. · Apply the cream to the external vaginal area morning and evening for 7 days. · Do not use tampons or douches during treatment. · Wear a panty liner to protect clothing from leakage. · Do not have sex until treatment is complete and symptoms resolve. · Wash hands before and after each application. · If symptoms last more than 7 days, see your healthcare provider. · Do not use if you are allergic to miconazole or any other ingredients. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Tell your doctor about all other medicines you take, especially blood thinners like warfarin. |